Farmson Basic Drugs Profile
Key Indicators
- Authorised Capital ₹ 3,893.50 Cr
as on 31-10-2024
- Paid Up Capital ₹ 3,891.87 Cr
as on 31-10-2024
- Company Age 4 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -28.87%
(FY 2023)
- Ebitda -28.87%
(FY 2023)
- Net Worth -0.48%
(FY 2023)
- Total Assets -0.47%
(FY 2023)
About Farmson Basic Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3,893.50 Cr and a paid-up capital of Rs 3,891.87 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Farmson Basic Drugs Private Limited India is Hiren Zaveri as COMPANY SECRETARY. Narshibhai Patel, Milin Mehta, Apurva Patel, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24110GJ2020PTC112370
- Company No.
112370
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jan 2020
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Farmson Basic Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hiren Zaveri  | Company Secretary | 31-Aug-2024 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vinit Menon | Director | 29-Jan-2020 | Current |
| Milin Mehta | Additional Director | 22-Mar-2024 | Current |
| Narshibhai Patel | Director | 29-Jan-2020 | Current |
Apurva Patel  | Additional Director | 22-Mar-2024 | Current |
| Komal Patel | Director | 29-Jan-2020 | Current |
| Sudhesh Mishra | Director | 29-Jan-2020 | Current |
Financial Performance and Corporate Structure Insights of Farmson Basic Drugs.
Farmson Basic Drugs Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 28.87% decrease in profit. The company's net worth dipped by a decrease of 0.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Farmson Basic Drugs?
In 2023, Farmson Basic Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Farmson Basic Drugs?
Farmson Basic Drugs has a workforce of 0 employees as of May 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Farmson Basic Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Farmson Basic Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
